Genscript Biotech Corporation
GNNSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $5 | $6 | $9 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $4 | $6 | $8 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -29.2% | 34.2% | 22.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 45.8% | 48.8% | 48.6% | 55.3% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 11.8% | -29.6% | -56.7% | -91.1% |
| Net Income | $3 | -$0 | -$0 | -$0 |
| % Margin | 498.2% | -11.4% | -36.3% | -70.2% |
| EPS Diluted | 1.36 | -0.045 | -0.11 | -0.18 |
| % Growth | 3,102.2% | 58.8% | 38.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |